Cracking the Code on Bispecific Antibody Characterization
Fellas, when you’re tackling the intricacies of bispecific antibodies, you're in for a ride. These things are no joke. Bio?Techne Corporation (NASDAQ: TECH), paired with Refeyn, is stepping up with a new workflow. It's a combo of icIEF fractionation and mass photometry, and it's making waves in the realm of biotherapeutics.
A Better Way to Handle Complexity
The complexity of bispecific antibodies is famous—or rather infamous—among bio-scientists. They’ve been a tough nut to crack. Characterizing their structure has been a real headache, causing delays and costly setbacks. Enter this new tech duo: by merging Bio?Techne's MauriceFlex™ system with Refeyn's TwoMP platform, we’ve got a fast-track four-hour workflow that exposes aggregation and size variants.
“Bispecifics are the fastest growing segment within next-generation antibodies, but they are very difficult to characterize" - Gerry Mackay, CEO of Refeyn.
Addressing Key Industry Challenges
Let’s face it, R&D on these complicated molecules often feels like a high-wire act without a net. But Bio?Techne and Refeyn are lowering the parachute. By aligning icIEF fractionation with mass photometry, developers sidestep reliance on several different tests. It's efficient, and frankly, it's about time.
- Integrated Workflow: Combines icIEF with mass photometry for direct characterization.
- Streamlined Process: Saves time and substance—nanogram-level samples, saving both time and resources.
- Efficient Development: Addresses aggregation within charge variants, minimizing development risks.
Accelerating Manufacturing and Reducing Risk
Under pressure could be the mantra here. As Will Geist of Bio?Techne puts it, their clientele is in a race against the clock and costs. The depth of characterizations they're now able to do means they’re not flying blind—it risks less, costs less, and gets decisions on the board faster.
By bagging a better handling of these variants, Bio?Techne and Refeyn are speeding up the manufacturing process, not to mention giving the green light to development cycles that were previously playing it cautious.
Anticipating Future Recognition
Their efforts were spotlighted at the American Society for Mass Spectrometry conference in San Diego. Big tradeshow, big stage, perfect stomping ground to reveal what they’re bringing to the table. It's not just an academic exercise either—a webinar demonstration used Mosunetuzumab?axgb and a biosimilar to illustrate size-related tweaks within charge variants. This is turning labs headlong into the future.
“Our customers are under intense pressure to develop and manufacture increasingly complex biologics faster and more efficiently." - Will Geist, Bio?Techne.
The insight, the innovation, it's all pointing towards a more stable future for biosimilar manufacturing. Now, whether this integrated approach will set new industry standards in both regulatory and manufacturing, that's something to keep your eyes on. The kind of efficiency promised doesn’t just reassure—it’s setting up for potential gains in market share.
Buzz belongs to those who pivot quickest with smart, pragmatic solutions, and right now, Bio?Techne and Refeyn are maneuvering into the fast lane. It's a strategic move, not just a tech flex, and that’s got real substance behind it.
Thinking Ahead
Look, to stay ahead in this industry, bets like these on advanced tech are the golden ticket. This workflow isn’t just a blip on the horizon; it’s essential for anyone tangled in the biosimilar rat race. If these companies carry forward and amplify their play, they might just set the standard everyone else in the industry will be scurrying to catch up to.
